UnitedHealth (UNH)
Market Price (12/27/2025): $331.4 | Market Cap: $300.2 BilSector: Health Care | Industry: Managed Health Care
UnitedHealth (UNH)
Market Price (12/27/2025): $331.4Market Cap: $300.2 BilSector: Health CareIndustry: Managed Health Care
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.5%, Dividend Yield is 2.6%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.3%, FCF Yield is 5.8% | Weak multi-year price returns2Y Excs Rtn is -80%, 3Y Excs Rtn is -114% | Key risksUNH key risks include [1] intense regulatory scrutiny and antitrust probes targeting its Medicare Advantage and Optum businesses, Show more. |
| Attractive cash flow generationCFO LTM is 21 Bil, FCF LTM is 17 Bil | ||
| Low stock price volatilityVol 12M is 47% | ||
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.5%, Dividend Yield is 2.6%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.3%, FCF Yield is 5.8% |
| Attractive cash flow generationCFO LTM is 21 Bil, FCF LTM is 17 Bil |
| Low stock price volatilityVol 12M is 47% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -80%, 3Y Excs Rtn is -114% |
| Key risksUNH key risks include [1] intense regulatory scrutiny and antitrust probes targeting its Medicare Advantage and Optum businesses, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
<b>1. Strong Third Quarter 2025 Earnings and Raised Outlook:</b> UnitedHealth Group reported consolidated revenues of $113.2 billion for the third quarter of 2025, representing a 12% year-over-year increase. The company also raised its full-year 2025 adjusted earnings outlook to at least $16.25 per share, indicating confidence in future performance. This positive financial update, released in October, likely contributed to a rebound in the stock price.
<br><br>
<b>2. Rebound from Earlier 2025 Declines and Depressed Valuation:</b> Throughout 2025, UnitedHealth Group's stock had experienced a significant decline, including being down approximately 35% year-to-date by December and reaching a 52-week low around $235 in August. This depressed valuation, coupled with its robust fundamentals, created an attractive entry point for investors, leading to a substantial rebound in the stock price during the latter half of the year.
<br><br>
<b>3. Strategic Acquisition of Amedisys:</b> The closing of the Amedisys acquisition on August 14, 2025, was a pivotal strategic move for UnitedHealth Group, expanding its presence in home health care. This acquisition was incorporated into the company's reaffirmed earnings expectations for 2025, signaling strategic growth and potentially boosting investor confidence.
<br><br>
<b>4. Management Actions to Address Medical Costs and Regulatory Challenges:</b> Earlier in 2025, UnitedHealth faced headwinds from unexpectedly high medical costs in its Medicare Advantage business and ongoing regulatory scrutiny, leading to margin compression. However, management outlined actions during the Q3 2025 earnings call aimed at stabilizing utilization trends and supporting margin recovery through disciplined repricing and medical cost management, which could have alleviated some investor concerns.
<br><br>
<b>5. Significant Institutional Investment Activity:</b> During the third quarter of 2025, OFI Invest Asset Management substantially increased its stake in UnitedHealth Group, acquiring an additional 69,352 shares, with holdings valued at approximately $48.6 million. Such significant institutional investment activity often indicates renewed confidence in a company's prospects and can positively influence stock performance.
Show moreStock Movement Drivers
Fundamental Drivers
The -2.9% change in UNH stock from 9/26/2025 to 12/26/2025 was primarily driven by a -19.7% change in the company's Net Income Margin (%).| 9262025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 341.78 | 331.83 | -2.91% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 422818.00 | 435159.00 | 2.92% |
| Net Income Margin (%) | 5.04% | 4.04% | -19.75% |
| P/E Multiple | 14.56 | 17.09 | 17.42% |
| Shares Outstanding (Mil) | 907.00 | 906.00 | 0.11% |
| Cumulative Contribution | -2.91% |
Market Drivers
9/26/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| UNH | -2.9% | |
| Market (SPY) | 4.3% | 42.5% |
| Sector (XLV) | 15.2% | 53.1% |
Fundamental Drivers
The 8.8% change in UNH stock from 6/27/2025 to 12/26/2025 was primarily driven by a 35.8% change in the company's P/E Multiple.| 6272025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 305.12 | 331.83 | 8.75% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 410057.00 | 435159.00 | 6.12% |
| Net Income Margin (%) | 5.39% | 4.04% | -25.02% |
| P/E Multiple | 12.59 | 17.09 | 35.78% |
| Shares Outstanding (Mil) | 912.00 | 906.00 | 0.66% |
| Cumulative Contribution | 8.75% |
Market Drivers
6/27/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| UNH | 8.8% | |
| Market (SPY) | 12.6% | 25.3% |
| Sector (XLV) | 17.0% | 51.2% |
Fundamental Drivers
The -33.5% change in UNH stock from 12/26/2024 to 12/26/2025 was primarily driven by a -46.9% change in the company's P/E Multiple.| 12262024 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 498.86 | 331.83 | -33.48% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 393898.00 | 435159.00 | 10.48% |
| Net Income Margin (%) | 3.63% | 4.04% | 11.21% |
| P/E Multiple | 32.16 | 17.09 | -46.85% |
| Shares Outstanding (Mil) | 923.00 | 906.00 | 1.84% |
| Cumulative Contribution | -33.51% |
Market Drivers
12/26/2024 to 12/26/2025| Return | Correlation | |
|---|---|---|
| UNH | -33.5% | |
| Market (SPY) | 15.8% | 12.6% |
| Sector (XLV) | 13.3% | 40.8% |
Fundamental Drivers
The -34.1% change in UNH stock from 12/27/2022 to 12/26/2025 was primarily driven by a -34.4% change in the company's Net Income Margin (%).| 12272022 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 503.62 | 331.83 | -34.11% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 315118.00 | 435159.00 | 38.09% |
| Net Income Margin (%) | 6.17% | 4.04% | -34.45% |
| P/E Multiple | 24.23 | 17.09 | -29.47% |
| Shares Outstanding (Mil) | 935.00 | 906.00 | 3.10% |
| Cumulative Contribution | -34.17% |
Market Drivers
12/27/2023 to 12/26/2025| Return | Correlation | |
|---|---|---|
| UNH | -33.9% | |
| Market (SPY) | 48.0% | 10.6% |
| Sector (XLV) | 18.2% | 42.3% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| UNH Return | 21% | 45% | 7% | 1% | -2% | -34% | 23% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| UNH Win Rate | 58% | 58% | 42% | 42% | 50% | 50% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| UNH Max Drawdown | -33% | -8% | -9% | -15% | -16% | -52% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL. See UNH Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | UNH | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -19.3% | -25.4% |
| % Gain to Breakeven | 24.0% | 34.1% |
| Time to Breakeven | 370 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -36.2% | -33.9% |
| % Gain to Breakeven | 56.7% | 51.3% |
| Time to Breakeven | 70 days | 148 days |
| 2018 Correction | ||
| % Loss | -24.3% | -19.8% |
| % Gain to Breakeven | 32.0% | 24.7% |
| Time to Breakeven | 243 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -72.4% | -56.8% |
| % Gain to Breakeven | 261.9% | 131.3% |
| Time to Breakeven | 1,229 days | 1,480 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
UnitedHealth's stock fell -19.3% during the 2022 Inflation Shock from a high on 10/31/2022. A -19.3% loss requires a 24.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe UnitedHealth (UNH):
- Amazon for healthcare: It's a massive, diversified company that touches many parts of the healthcare system, from health insurance to pharmacy benefits management, physician services, and data analytics.
- CVS Health, but on a vastly larger and more integrated scale: Similar to how CVS Health combines pharmacies, an insurance company (Aetna), and a PBM (Caremark), UnitedHealth owns the giant UnitedHealthcare insurance arm and the even larger Optum division, spanning pharmacy benefits, clinics, data analytics, and care delivery.
- The Walmart of health insurance: It's the dominant, largest player in the health insurance market, with a broad reach across employer, Medicare, and Medicaid plans, and is increasingly owning and managing health services (like clinics and pharmacy benefits) too.
AI Analysis | Feedback
- Health Insurance Plans: Provides comprehensive medical and ancillary health benefits to individuals, employers, and government programs (Medicare and Medicaid).
- Pharmacy Benefit Management (PBM): Manages prescription drug benefits for health plans, employers, and government entities, including drug procurement, formulary management, and mail-order pharmacy services.
- Healthcare Delivery Services: Offers direct patient care through a network of primary, urgent, and specialty care clinics, as well as behavioral health and virtual care platforms.
- Healthcare Technology & Consulting: Delivers data analytics, software solutions, and advisory services to healthcare providers, payers, and life sciences organizations to enhance operational efficiency and clinical outcomes.
AI Analysis | Feedback
UnitedHealth (symbol: UNH) serves a diverse base of customers, primarily individuals, through various channels. Its core business revolves around providing health benefit plans and health services to a wide range of populations.
The major categories of individual customers that UnitedHealth serves include:
- Individuals covered by Employer-Sponsored Plans: This category encompasses employees and their dependents whose health insurance benefits are provided through plans sponsored by their employers. While the employer is the direct payer to UnitedHealth, the employees and their families are the ultimate customers utilizing the healthcare services and benefits.
- Seniors and Individuals with Disabilities: These customers are members enrolled in UnitedHealth's Medicare Advantage, Medicare Supplement, and Medicare Part D plans. They either purchase these plans directly or are covered through government-sponsored programs where UnitedHealth acts as the managed care provider for this demographic.
- Individuals Covered by Government-Sponsored Programs (e.g., Medicaid): This category includes low-income individuals and families, as well as other specific populations, who receive health benefits through state or federal government programs for which UnitedHealth provides managed care services under contract with governmental entities.
AI Analysis | Feedback
nullAI Analysis | Feedback
Stephen J. Hemsley, Chairman & CEO
Stephen J. Hemsley is the Chairman and Chief Executive Officer of UnitedHealth Group, having been reappointed to the CEO role in May 2025. He previously served as CEO from 2006 to 2017. Before rejoining UnitedHealth Group in 1997, Mr. Hemsley was a managing partner in strategy and planning and chief financial officer for Arthur Andersen, LLP. He has also served on the board of Cargill, a global food and agriculture corporation. During his first tenure as CEO, UnitedHealth Group notably created Optum, its health services arm.
Wayne S. DeVeydt, Chief Financial Officer
Wayne S. DeVeydt was appointed Chief Financial Officer of UnitedHealth Group, effective September 2, 2025. Prior to this role, he served as a managing director and operating partner at Bain Capital, a private equity firm. From 2018 to 2020, Mr. DeVeydt was the chairman and CEO of Surgery Partners, Inc., and he was also the CFO of Anthem, Inc. (now Elevance) from 2007 to 2016. Earlier in his career, he was a partner at PricewaterhouseCoopers LLP, with a focus on the healthcare sector.
Patrick Conway, CEO, Optum Health
Patrick Conway was appointed Chief Executive Officer of Optum Health, effective July 2025. He joined UnitedHealth Group in early 2020 as CEO of Optum Rx. Dr. Conway previously served as President and CEO of Blue Cross and Blue Shield of North Carolina from 2017 to 2019. From 2011 to 2017, he was the Deputy Administrator for Innovation and Quality at the federal Centers for Medicare and Medicaid Services (CMS), and also served as the Director of the Center for Medicare and Medicaid Innovation (CMMI) and the agency's Chief Medical Officer. He remains a practicing pediatric hospitalist.
Tim Noel, CEO, UnitedHealthcare
Tim Noel was named CEO of UnitedHealthcare, UnitedHealth Group's health insurance business, in January 2025. He joined UnitedHealth Group in 2007 and has nearly two decades of experience with the company. Most recently, he served as chief executive of UnitedHealthcare's Medicare & Retirement division. Mr. Noel has held a series of finance and operations roles within the company.
Heather Cianfrocco, Executive Vice President, Governance, Compliance and Information Security
Heather Cianfrocco was appointed UnitedHealth Group's Executive Vice President of Governance, Compliance and Information Security in April 2025. She previously served as the CEO of Optum. Ms. Cianfrocco has held various senior leadership roles across both UnitedHealthcare and Optum and has a decade of experience working as a lawyer.
AI Analysis | Feedback
UnitedHealth (UNH) faces several significant risks to its business operations and financial performance. The most significant key risks include:1. Regulatory Scrutiny and Policy Changes
UnitedHealth is subject to intense and broad regulatory scrutiny from various government bodies. This includes ongoing investigations by the U.S. Department of Justice (DOJ) into alleged Medicare fraud, specifically concerning inflated risk scores (upcoding) to secure higher reimbursements in its Medicare Advantage (MA) program. There are also antitrust probes targeting Optum's vertical integration, particularly its pharmacy benefit management (PBM) business, which could lead to substantial fines, forced divestitures, or fundamental changes to its business model. Furthermore, the company is vulnerable to broader regulatory changes in healthcare policy, especially those affecting Medicare Advantage, which can directly impact its operations and profitability. Allegations of undisclosed payments to nursing homes and improper denial of health coverage also contribute to this risk area.2. Rising Medical Costs and Increased Utilization
Higher-than-expected medical costs and increased healthcare utilization represent a major ongoing pressure on UnitedHealth's profit margins, particularly within its Medicare Advantage plans. The company has experienced significant increases in its Medical Benefits Ratio (MBR) and Medical Care Ratio (MCR), reflecting the higher percentage of premium revenue spent on medical care. This surge in utilization, partly attributed to a post-pandemic return for deferred procedures, has forced UnitedHealth to revise its financial guidance and outlook, indicating a direct impact on profitability.3. Cybersecurity Risks and Attacks
UnitedHealth faces significant threats from cybersecurity incidents, as highlighted by the February 2024 ransomware attack on its subsidiary, Change Healthcare. This attack disrupted Medicare and Medicaid payments, leading to substantial financial costs (exceeding $3 billion in 2024) and reputational damage. The persistent threat of such breaches necessitates ongoing significant cybersecurity investments and poses a risk of future operational disruptions and financial liabilities.AI Analysis | Feedback
Government regulation targeting Pharmacy Benefit Managers (PBMs).
AI Analysis | Feedback
UnitedHealth Group operates primarily through two main segments: UnitedHealthcare, which provides health insurance and benefits, and Optum, which offers an array of health services including pharmacy care services, healthcare technology, and care delivery.
UnitedHealthcare (Health Insurance/Benefits)
- U.S. Health Insurance Market: The United States health insurance market was valued at approximately USD 1.6 trillion in 2024. This market is driven by factors such as rising healthcare costs, an aging population, and the expansion of Affordable Care Act subsidies. Another estimate indicates the market was valued at USD 1.23 trillion in 2024 and is expected to reach USD 1.77 trillion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 6.98%.
Optum (Healthcare Services)
The overall addressable market for Optum's services is substantial:
- Overall Optum Services: The U.S. addressable market for Optum services is estimated at more than $850 billion. The international market is estimated at nearly $600 billion. The combined global health services market opportunity that Optum addresses is over $1.4 trillion.
Breaking down Optum's main product areas:
- Optum Rx (Pharmacy Benefit Management - PBM): The U.S. pharmacy benefit management market size was valued at USD 587.4 billion in 2024. Another source states the U.S. market was USD 555.84 billion in 2024 and is projected to grow from USD 609.13 billion in 2025 to USD 898.77 billion by 2032, exhibiting a CAGR of 5.7%. The global pharmacy benefit management market size was valued at USD 573.27 billion in 2024.
- Optum Insight (Healthcare IT, Data & Analytics, Technology, Operations): The U.S. healthcare IT market size was USD 160.52 billion in 2024 and is projected to reach USD 566.48 billion by 2034, expanding at a CAGR of 13.44%. The global healthcare IT market size was valued at USD 761.68 billion in 2024 and is projected to grow to USD 3,257.26 billion by 2034, exhibiting a CAGR of 15.6%.
- Optum Health (Care Delivery, Population Health Management, Value-Based Healthcare): The U.S. value-based healthcare service market size was valued at USD 4.01 trillion in 2024 and is expected to grow at a CAGR of 7.4% from 2025 to 2030. The North America healthcare services market size was USD 4.01 trillion in 2024, with the U.S. market standing at USD 3.78 trillion in 2024. This market is expected to grow to USD 8.41 trillion by 2032, exhibiting a CAGR of 9.7%.
AI Analysis | Feedback
UnitedHealth Group (UNH) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
- Expansion of Optum Segments: Growth in the Optum segment, particularly Optum Rx and Optum Health, is a significant driver. Optum Rx has demonstrated robust revenue increases due to new client acquisitions and expanded relationships with existing clients, alongside growth in prescription volumes. Optum Health is concentrating on expanding its value-based care models, aiming to add a substantial number of new patients and deepen its presence in both existing and new geographic markets and services.
- Growth in UnitedHealthcare's Government Programs: Despite facing pressures in Medicare Advantage due to funding reductions and repricing, UnitedHealthcare's Medicare & Retirement and Community & State divisions are expected to contribute to revenue growth. The company is focusing on serving a growing number of domestic consumers, particularly in these segments, driven by an increased focus on individuals with complex needs and improvements in Medicaid rates. While there is an expected contraction in overall Medicare Advantage membership in 2026 due to disciplined pricing, the strategic focus is on margin growth and a return to consistent performance by 2026.
- Strategic Acquisitions: UnitedHealth Group recently completed the acquisition of Amedisys in August 2025, which is anticipated to contribute to revenue. The company also plans to resume its historical capital deployment strategies, including strategic acquisitions, in the latter half of 2026, which will further support long-term growth initiatives.
- Investments in Technology and AI: Ongoing investments in technology and artificial intelligence are highlighted as crucial for enhancing efficiency and improving the customer experience. These advancements are expected to streamline processes, such as AI-powered claims processing tools, and enhance service delivery, thereby indirectly contributing to revenue growth through improved operational leverage and competitive advantage.
- Pricing Actions and Margin Improvement: UnitedHealth Group is implementing repricing efforts within UnitedHealthcare to drive solid operating earnings growth and improve margins. The company has submitted average rate increases of over 25% for ACA plans and is targeting commercial margins of 7-9% by 2027, with meaningful progress expected in 2026 through pricing actions and cost control. This strategic focus on optimizing pricing and improving profitability will be a key driver of future revenue expansion.
AI Analysis | Feedback
Share Repurchases
- UnitedHealth Group repurchased approximately $9 billion in common stock in 2024.
- The company repurchased approximately $8 billion in common stock in 2023.
- In 2022, common stock repurchases amounted to approximately $7 billion.
Share Issuance
- UnitedHealth Group's shares outstanding have consistently declined, from 0.94 billion in 2020 to 0.905 billion as of November 2025, indicating net share repurchases rather than significant issuance.
Outbound Investments
- UnitedHealth Group completed the acquisition of Change Healthcare for approximately $8 billion in October 2022.
- In February 2023, the company closed its $5.4 billion acquisition of LHC Group.
- UnitedHealth Group announced the acquisition of Amedisys for about $3.3 billion in June 2023, a deal that faced regulatory scrutiny from the U.S. Department of Justice in November 2024.
Capital Expenditures
- UnitedHealth Group's capital expenditures for fiscal year 2024 were $3.499 billion.
- The company's capital expenditures are projected to be $3.683 billion for 2025, $4.008 billion for 2026, and $4.206 billion for 2027.
- Capital expenditures are primarily focused on investments in technology-driven health services, digital tools, and capabilities to support value-based care and pharmacy services.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to UNH. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
| 05312025 | UNH | UnitedHealth | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 10.7% | 12.1% | -20.7% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for UnitedHealth
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 175.78 |
| Mkt Cap | 292.8 |
| Rev LTM | 61,549 |
| Op Inc LTM | 12,268 |
| FCF LTM | 12,294 |
| FCF 3Y Avg | 12,816 |
| CFO LTM | 13,614 |
| CFO 3Y Avg | 14,117 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.4% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | 9.4% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 12.1% |
| Op Mgn 3Y Avg | 12.0% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 14.6% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 11.6% |
| FCF/Rev 3Y Avg | 12.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 292.8 |
| P/S | 2.7 |
| P/EBIT | 21.2 |
| P/E | 33.0 |
| P/CFO | 17.7 |
| Total Yield | 5.2% |
| Dividend Yield | 2.1% |
| FCF Yield 3Y Avg | 5.7% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.0% |
| 3M Rtn | 4.9% |
| 6M Rtn | 12.0% |
| 12M Rtn | 10.1% |
| 3Y Rtn | 73.6% |
| 1M Excs Rtn | -1.1% |
| 3M Excs Rtn | 0.6% |
| 6M Excs Rtn | -0.3% |
| 12M Excs Rtn | -4.6% |
| 3Y Excs Rtn | -6.2% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| UnitedHealthcare | 281,360 | 249,741 | 222,899 | 200,875 | 193,842 |
| Optum Rx | 116,087 | 99,773 | 35,535 | 35,078 | 32,195 |
| Optum Health | 95,319 | 71,174 | 24,831 | 17,327 | 12,351 |
| Optum Insight | 18,932 | 14,581 | 4,332 | 3,861 | 3,767 |
| Optum Eliminations | -3,703 | -2,760 | |||
| Corporate and Eliminations | -136,373 | -108,347 | |||
| Total | 371,622 | 324,162 | 287,597 | 257,141 | 242,155 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| UnitedHealthcare | 16,415 | 14,379 | 11,975 | 12,359 | 10,326 |
| Optum Health | 6,560 | 6,032 | 4,462 | 3,434 | 2,963 |
| Optum Rx | 5,115 | 4,436 | 4,135 | 3,887 | 3,902 |
| Optum Insight | 4,268 | 3,588 | 3,398 | 2,725 | 2,494 |
| Corporate and Eliminations | 0 | 0 | |||
| Optum Eliminations | 0 | 0 | |||
| Total | 32,358 | 28,435 | 23,970 | 22,405 | 19,685 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| UnitedHealthcare | 110,943 | 107,094 | 102,967 | 98,229 | 88,250 |
| Optum Health | 89,432 | 68,950 | 60,474 | 52,073 | 40,444 |
| Optum Rx | 51,266 | 47,476 | 40,181 | 39,280 | 36,346 |
| Optum Insight | 34,173 | 31,090 | 16,868 | 15,425 | 15,181 |
| Optum Eliminations | 0 | 0 | |||
| Corporate and Eliminations | -12,094 | -8,905 | -8,284 | -7,718 | -6,332 |
| Total | 273,720 | 245,705 | 212,206 | 197,289 | 173,889 |
Price Behavior
| Market Price | $331.83 | |
| Market Cap ($ Bil) | 300.6 | |
| First Trading Date | 03/26/1990 | |
| Distance from 52W High | -43.5% | |
| 50 Days | 200 Days | |
| DMA Price | $333.20 | $347.23 |
| DMA Trend | down | down |
| Distance from DMA | -0.4% | -4.4% |
| 3M | 1YR | |
| Volatility | 26.4% | 47.4% |
| Downside Capture | 117.16 | 42.45 |
| Upside Capture | 79.22 | -4.11 |
| Correlation (SPY) | 42.3% | 12.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.62 | 0.95 | 0.90 | 0.92 | 0.27 | 0.26 |
| Up Beta | -0.14 | 0.58 | 0.14 | 0.86 | 0.49 | 0.44 |
| Down Beta | -1.55 | 1.09 | 1.13 | 1.60 | 0.11 | 0.19 |
| Up Capture | 73% | 71% | 106% | 63% | -10% | 1% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 7 | 20 | 32 | 64 | 123 | 384 |
| Down Capture | 133% | 118% | 97% | 69% | 56% | 54% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 12 | 21 | 30 | 61 | 125 | 366 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of UNH With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| UNH | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -32.0% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.3% |
| Annualized Volatility | 47.2% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | -0.65 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 40.9% | 12.6% | 1.2% | -5.7% | 12.3% | 2.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of UNH With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| UNH | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 1.1% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 29.6% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.7% |
| Sharpe Ratio | 0.08 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 51.3% | 24.8% | 2.7% | 1.9% | 20.7% | 7.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of UNH With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| UNH | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 12.6% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 29.0% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.46 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 64.8% | 48.1% | 0.9% | 13.2% | 39.9% | 10.4% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/28/2025 | 0.5% | -8.8% | -10.8% |
| 7/29/2025 | -7.5% | -14.6% | 6.5% |
| 4/17/2025 | -22.4% | -27.5% | -50.1% |
| 1/16/2025 | -6.0% | -2.5% | -3.7% |
| 10/15/2024 | -8.1% | -5.6% | 1.5% |
| 7/16/2024 | 6.5% | 8.4% | 11.4% |
| 4/16/2024 | 5.2% | 10.2% | 15.3% |
| 1/12/2024 | -3.4% | -6.7% | -4.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 11 | 15 |
| # Negative | 11 | 13 | 9 |
| Median Positive | 3.8% | 4.3% | 6.1% |
| Median Negative | -2.9% | -2.6% | -6.7% |
| Max Positive | 7.2% | 12.6% | 15.3% |
| Max Negative | -22.4% | -27.5% | -50.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 10282025 | 10-Q 9/30/2025 |
| 6302025 | 8112025 | 10-Q 6/30/2025 |
| 3312025 | 5072025 | 10-Q 3/31/2025 |
| 12312024 | 2272025 | 10-K 12/31/2024 |
| 9302024 | 11042024 | 10-Q 9/30/2024 |
| 6302024 | 8092024 | 10-Q 6/30/2024 |
| 3312024 | 5092024 | 10-Q 3/31/2024 |
| 12312023 | 2282024 | 10-K 12/31/2023 |
| 9302023 | 11062023 | 10-Q 9/30/2023 |
| 6302023 | 8022023 | 10-Q 6/30/2023 |
| 3312023 | 5032023 | 10-Q 3/31/2023 |
| 12312022 | 2242023 | 10-K 12/31/2022 |
| 9302022 | 11022022 | 10-Q 9/30/2022 |
| 6302022 | 8032022 | 10-Q 6/30/2022 |
| 3312022 | 5042022 | 10-Q 3/31/2022 |
| 12312021 | 2152022 | 10-K 12/31/2021 |
Insider Activity
Expand for More| Owner | Title | Filing Date | Action | Price | Shares | TransactedValue | Value ofHeld Shares | Form | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | Baker Charles D. | 9152025 | Sell | 356.05 | 27 | 9,613 | Form | ||
| 1 | Conway Patrick Hugh | Chief Executive Officer, Optum | 6122025 | Sell | 305.00 | 589 | 179,645 | 3,171,528 | Form |
| 2 | REX JOHN F | President & CFO | 5162025 | Buy | 291.12 | 17,175 | 4,999,919 | 59,328,308 | Form |
| 3 | HEMSLEY STEPHEN J | CEO, UHG | 5162025 | Buy | 288.57 | 86,700 | 25,019,019 | 196,081,278 | Form |
| 4 | FLYNN TIMOTHY PATRICK | 5162025 | Buy | 320.80 | 1,533 | 491,786 | 1,935,386 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.